Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

NCT02429505 is registered in ClinicalTrials.gov with Knight Therapeutics (USA) Inc as lead sponsor.

NCT NCT02429505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02429505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Lead sponsor
Knight Therapeutics (USA) Inc
Phase
Observational
Overall status
Withdrawn
Start date
July 31, 2015
Completion date
March 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis